Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + anlotinib + radiotherapy holiday-mode first-line study in driver-negative metastatic NSCLC
ChiCTR2500104150Phase 2Recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and anlotinib in non-small cell lung cancer (NSCLC), sponsored by Anhui Provincial Tumor Hospital. Primary endpoint: Objective response rate. Started Jun 2025; status: recruiting.
02
Drugs
sintilimabanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500104150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104150.